Search

    Language Settings
    Select Website Language

    GDPR Compliance

    We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

    BijnorNews
    Bijnor news

    Bambusa Therapeutics Files for IPO To Fund Eczema Drug Trials

    14 hours ago

    Started in 2024, Bambusa secured its lead drug candidates through its earlier acquisition of assets from a unit of BioNTech SE, the first to treat atopic dermatitis, commonly known as eczema, and the second to treat other inflammatory disorders including respiratory and allergic diseases.
    Click here to Read More
    Previous Article
    Bessent Will Likely Cut US Long Bond Sales Next Month, Says Citi
    Next Article
    India To Remain Fastest-Growing Large Economy At 7.3% In 2026, Says UNCTAD

    Related Business Updates:

    Are you sure? You want to delete this comment..! Remove Cancel

    Comments (0)

      Leave a comment